Ceclofen100 mg

Ceclofen 100 mg is a potent non-steroidal anti-inflammatory drug (NSAID) indicated for the relief of pain and inflammation across a wide range of acute and chronic musculoskeletal conditions. It is widely prescribed in clinical practice for both short-term symptomatic management and long-term maintenance therapy in inflammatory joint diseases.

Approved Indications

• Osteoarthritis – Reduces joint pain, stiffness, and swelling caused by the progressive degeneration of cartilage in weight-bearing joints such as the knee, hip, and spine.
• Rheumatoid Arthritis – Provides symptomatic relief from the chronic inflammation, morning stiffness, joint swelling, and tenderness associated with this autoimmune joint disease.
• Ankylosing Spondylitis – Alleviates spinal inflammation, back pain, and progressive stiffness in this chronic inflammatory disease affecting the sacroiliac joints and spine.
• Toothache (Dental Pain) – Offers effective short-term analgesic relief from acute dental pain and post-dental procedure discomfort.
• Trauma-Related Pain – Used for pain management following musculoskeletal injuries, fractures, sprains, and strains.
• Lumbago (Low Back Pain) – Relieves acute and subacute lower back pain of musculoskeletal origin, including lumbar muscle spasm and lumbar spondylosis.

Other Potential Uses

In addition to the above approved indications, Ceclofen 100 mg may be used under physician supervision for conditions involving acute soft-tissue inflammation, post-operative pain, periarthritis, tendinitis, and bursitis. Always consult a registered physician before initiating Ceclofen 100 mg therapy.

Important: Ceclofen 100 mg should only be taken under the direction of a licensed healthcare provider. Self-medication with NSAIDs carries significant risk of gastrointestinal, cardiovascular, and renal adverse effects.

Drug Classification

Ceclofen 100 mg is a phenylacetic acid derivative belonging to the class of non-steroidal anti-inflammatory drugs (NSAIDs). It possesses potent analgesic, anti-inflammatory, and antipyretic properties, making it effective across a broad spectrum of pain and inflammatory disorders.

Mechanism of Action

Ceclofen 100 mg exerts its primary pharmacological action through the potent inhibition of cyclooxygenase (COX) enzymes — specifically COX-1 and COX-2 — which are the key enzymes responsible for the biosynthesis of prostaglandins from arachidonic acid. Prostaglandins are lipid mediators that play a central role in sensitizing peripheral pain receptors, promoting vasodilation, and driving the inflammatory cascade at sites of tissue injury or disease.

By blocking COX enzyme activity, Ceclofen 100 mg significantly reduces local prostaglandin concentrations, thereby attenuating pain perception, reducing fever, and suppressing inflammation. In vitro studies suggest that Ceclofen 100 mg may preferentially inhibit COX-2 at therapeutic concentrations compared to many other traditional NSAIDs, which may contribute to a relatively improved gastrointestinal tolerability profile.

Additionally, Ceclofen 100 mg is partially metabolized to diclofenac, a well-known NSAID, which also contributes to its overall anti-inflammatory effect. This dual mechanism may account for Ceclofen 100 mg's potent analgesic and anti-inflammatory efficacy.

Pharmacokinetic Profile

• Absorption: Ceclofen 100 mg is rapidly and completely absorbed after oral administration. It is absorbed as an unchanged drug from the gastrointestinal tract, with peak plasma concentrations typically reached within 1–3 hours.
• Protein Binding: Highly protein-bound (>99%), primarily to plasma albumin, which limits its volume of distribution.
• Metabolism: Extensively metabolized in the liver via the cytochrome P450 enzyme system (primarily CYP2C9). A significant metabolite is diclofenac, which retains pharmacological activity.
• Elimination: Primarily excreted in the urine as glucuronide conjugates of the parent drug and its metabolites. The elimination half-life is approximately 4–4.3 hours.
• Onset of Action: Analgesic relief is typically experienced within 30–60 minutes of oral administration for immediate-release formulations.

Formulation Advantages

Ceclofen 100 mg is available in both 100 mg film-coated tablets (immediate release) and 200 mg extended-release (ER/SR) tablets (sustained release). The extended-release formulation maintains more stable plasma drug concentrations throughout the day, reducing dosing frequency and improving patient adherence in long-term inflammatory conditions.

Although no clinically significant drug interactions with Ceclofen 100 mg have been formally established in all cases, close monitoring is essential when it is co-administered with the following drug classes or agents. Like all NSAIDs, Ceclofen 100 mg has the potential to alter the pharmacokinetics or pharmacodynamics of several commonly used medications.

Known & Clinically Significant Interactions

Lithium

Ceclofen 100 mg may increase plasma concentrations of lithium by reducing its renal clearance. Patients receiving lithium therapy should be closely monitored for signs of lithium toxicity (nausea, tremor, confusion, polyuria) if Ceclofen 100 mg is initiated, adjusted, or discontinued. Lithium dose adjustment may be necessary.

Digoxin

Concomitant use may lead to elevated serum digoxin levels, increasing the risk of digoxin toxicity (bradycardia, heart block, visual disturbances). Regular monitoring of serum digoxin concentrations and cardiac function is recommended during co-administration.

Diuretics (Thiazides & Loop Diuretics)

Ceclofen 100 mg may reduce the diuretic and antihypertensive efficacy of both thiazide and loop diuretics by inhibiting renal prostaglandin synthesis. This interaction can also increase the risk of acute renal impairment, particularly in volume-depleted patients. Blood pressure and renal function should be monitored.

Anticoagulants (e.g., Warfarin)

Ceclofen 100 mg may potentiate the anticoagulant effect of warfarin and other coumarin-type anticoagulants, increasing the risk of bleeding, particularly gastrointestinal haemorrhage. Concurrent use requires frequent monitoring of INR/prothrombin time and potential dose adjustment of the anticoagulant.

Methotrexate

NSAIDs including Ceclofen 100 mg may reduce the renal tubular secretion of methotrexate, leading to elevated plasma methotrexate levels and potentially serious toxicity (haematological, hepatic, and renal). This combination should be used with extreme caution, particularly in patients receiving high-dose methotrexate therapy. Methotrexate levels and signs of toxicity should be closely monitored.

Other Interactions to Consider

• Other NSAIDs or Aspirin: Concurrent use increases the risk of gastrointestinal ulceration and bleeding without additional therapeutic benefit. Avoid combined NSAID therapy.
• ACE Inhibitors & Angiotensin Receptor Blockers (ARBs): May diminish antihypertensive effects and increase the risk of acute kidney injury, especially in elderly or volume-depleted patients.
• Corticosteroids: Combined use increases the risk of gastrointestinal adverse effects, including ulceration and perforation.
• SSRIs (Selective Serotonin Reuptake Inhibitors): Co-administration may increase the risk of gastrointestinal bleeding.
• Cyclosporine: NSAIDs may increase the nephrotoxic potential of cyclosporine. Renal function monitoring is advisable.

Note: Always inform your physician and pharmacist about all prescription medications, over-the-counter drugs, herbal supplements, and vitamins you are currently taking before starting Ceclofen 100 mg.

Like all NSAIDs, Ceclofen 100 mg may cause a range of adverse effects. Most side effects are dose-dependent and tend to resolve upon dose reduction or discontinuation of the drug. Patients should be counselled to report any unusual or persistent symptoms to their physician promptly.

Gastrointestinal (Most Common)

Gastrointestinal side effects are the most frequently reported adverse reactions with Ceclofen 100 mg, consistent with its COX-1 inhibitory activity affecting the gastric mucosal lining.

• Nausea and vomiting
• Dyspepsia (indigestion, heartburn)
• Abdominal pain or discomfort
• Diarrhoea or constipation
• Flatulence and bloating
• Gastritis and gastric irritation
• Peptic ulceration (especially with prolonged use) — may be accompanied by bleeding or perforation in severe cases

Central Nervous System

• Headache
• Dizziness or vertigo
• Drowsiness or somnolence
• Insomnia (less common)

Dermatological

• Skin rash or erythema
• Pruritus (itching)
• Urticaria (hives)
• Photosensitivity reactions (rare)
• Severe skin reactions such as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis (very rare but serious — discontinue immediately)

Hepatic

• Elevated liver enzymes (ALT, AST) — usually reversible upon discontinuation
• Hepatitis or jaundice (rare)

Renal

• Fluid retention and peripheral oedema
• Elevated serum creatinine (indicative of renal stress)
• Acute renal insufficiency — particularly in patients with pre-existing renal impairment, heart failure, or volume depletion

Cardiovascular

• Peripheral oedema
• Hypertension or worsening of pre-existing hypertension
• Increased risk of serious cardiovascular events (myocardial infarction, stroke) — associated with prolonged high-dose NSAID use, particularly in patients with existing cardiovascular disease

Haematological (Rare)

• Thrombocytopenia (low platelet count)
• Anaemia (particularly with chronic gastrointestinal blood loss)
• Prolonged bleeding time

Hypersensitivity Reactions (Rare but Serious)

• Bronchospasm or exacerbation of asthma
• Angioedema
• Anaphylactic or anaphylactoid reactions

When to seek immediate medical attention: Stop taking Ceclofen 100 mg and contact your doctor immediately if you experience signs of gastrointestinal bleeding (black or tarry stools, vomiting blood), severe skin reactions, chest pain, sudden swelling of the face or throat, difficulty breathing, or signs of liver or kidney problems (yellowing of skin or eyes, dark urine, significant reduction in urine output).

Use During Pregnancy

The use of Ceclofen 100 mg during pregnancy should be avoided unless the potential benefit to the mother clearly outweighs the possible risks to the fetus. As with all NSAIDs, Ceclofen 100 mg inhibits prostaglandin synthesis, which plays a critical role in fetal development and the maintenance of pregnancy.

First Trimester

Use during the first trimester should be approached with caution. Some epidemiological studies have suggested a possible association between NSAID use in early pregnancy and an increased risk of miscarriage and congenital malformations, although causality has not been conclusively established. Ceclofen 100 mg should only be used in the first trimester if strictly necessary and under close medical supervision.

Second Trimester

Use in the second trimester should be limited to cases where the benefit clearly outweighs the risk. The physician should use the lowest effective dose for the shortest possible duration.

Third Trimester (Contraindicated)

Ceclofen 100 mg is contraindicated in the third trimester of pregnancy. During this period, NSAIDs are known to carry the following serious fetal risks:

• Premature closure of the ductus arteriosus, which can lead to fetal pulmonary hypertension and right heart failure.
• Renal dysfunction in the fetus, potentially resulting in oligohydramnios (reduced amniotic fluid) — associated with fetal limb contractures, delayed lung maturation, and neonatal renal failure.
• Inhibition of platelet aggregation in the neonate, increasing the risk of neonatal bleeding.
• Delayed or prolonged labour due to inhibition of prostaglandin-mediated uterine contractions.

Use During Lactation (Breastfeeding)

The use of Ceclofen 100 mg during breastfeeding should be avoided. It is not conclusively known whether Ceclofen 100 mg or its active metabolites are excreted into human breast milk, but as a metabolite of diclofenac (a known NSAID), there is a theoretical risk of exposure to the breastfed infant. If NSAID therapy is essential during lactation, a physician should evaluate the benefit-to-risk ratio and may consider alternative agents with a better-established safety profile in nursing mothers.

Fertility

As with other NSAIDs, Ceclofen 100 mg may impair female fertility by inhibiting prostaglandin-dependent follicular rupture necessary for ovulation. Women who are planning to conceive or are undergoing fertility treatment should avoid Ceclofen 100 mg. This effect is reversible upon discontinuation of the drug.

Recommendation: Always consult your obstetrician or healthcare provider before using any NSAID during pregnancy or while breastfeeding.

Ceclofen 100 mg should be used with care in specific patient populations and clinical settings. Prior to initiating therapy, the patient's complete medical history should be reviewed, and ongoing monitoring should be maintained during prolonged use.

Gastrointestinal Precautions

Particular caution should be exercised in patients with a history of or active peptic ulcer disease, gastritis, gastrointestinal bleeding, or inflammatory bowel disease (Crohn's disease or ulcerative colitis). NSAIDs including Ceclofen 100 mg can cause serious gastrointestinal adverse events — including ulceration, bleeding, and perforation — which can occur at any time during use and without prior warning symptoms. The risk is higher in elderly patients and those receiving concomitant corticosteroids, anticoagulants, or antiplatelet agents. Co-prescription of a proton pump inhibitor (PPI) or misoprostol is recommended for high-risk individuals.

Hepatic Precautions

Caution should be exercised in patients with moderate-to-severe hepatic impairment, as reduced hepatic metabolism may result in drug accumulation. Ceclofen 100 mg is contraindicated in severe hepatic failure. Liver function tests should be monitored periodically during long-term therapy. If signs of hepatotoxicity appear (jaundice, elevated transaminases, right upper quadrant pain), Ceclofen 100 mg should be discontinued immediately.

Renal Precautions

Ceclofen 100 mg, like other NSAIDs, may reduce renal blood flow and glomerular filtration rate by inhibiting prostaglandin-mediated renal vasodilation — particularly in patients with pre-existing renal impairment, heart failure, liver cirrhosis, or those who are volume-depleted (e.g., receiving diuretics). Such patients require careful monitoring of serum creatinine and electrolytes. Ceclofen 100 mg should be avoided in patients with creatinine clearance below 30 mL/min.

Cardiovascular Precautions

Patients with a history of cardiac disease, hypertension, or congestive heart failure should use Ceclofen 100 mg with caution. NSAIDs may cause fluid retention and oedema, worsen existing hypertension, and increase the risk of major cardiovascular events (myocardial infarction and stroke), particularly with high-dose, long-term use. The lowest effective dose for the shortest duration should always be used.

Dizziness & Urticaria

Patients who experience dizziness, vertigo, or urticaria during Ceclofen 100 mg therapy should be monitored and the drug discontinued if reactions are clinically significant. Patients experiencing dizziness should refrain from driving or operating heavy machinery until symptoms resolve.

Asthma & Respiratory Precautions

Ceclofen 100 mg should be used with extreme caution, or avoided entirely, in patients with known aspirin-sensitive asthma or a history of NSAID-triggered bronchospasm. Cross-sensitivity between different NSAIDs is well documented in this patient population.

Elderly Patients

Elderly patients are at significantly higher risk of serious gastrointestinal, renal, and cardiovascular adverse effects from NSAID therapy. The lowest effective dose for the shortest duration must be employed, with regular clinical and biochemical monitoring including renal function tests, blood pressure, and haematological parameters.

Driving & Use of Machinery

Ceclofen 100 mg may cause dizziness and drowsiness in some patients. Until the individual patient's response to Ceclofen 100 mg is established, caution is advised when driving or operating potentially hazardous machinery.

Haematological Effects

As with all NSAIDs, Ceclofen 100 mg inhibits platelet aggregation and prolongs bleeding time. Patients with coagulation disorders or those receiving anticoagulant or antiplatelet therapy (including low-dose aspirin) require close monitoring for signs of abnormal bleeding.

Proper storage of Ceclofen 100 mg is essential to maintain its stability, potency, and safety. Follow the storage instructions below to ensure the medicine remains effective throughout its shelf life.

• Temperature: Store in a cool, dry place at or below 30°C. Avoid exposure to excessive heat, which may degrade the active ingredient and alter the tablet coating.
• Light: Keep protected from direct sunlight and artificial light. Store in the original packaging or an opaque, light-resistant container to prevent photodegradation.
• Moisture: Store in a dry environment, away from areas of high humidity such as bathrooms or kitchens. Moisture can accelerate tablet breakdown and microbial contamination.
• Children's Safety: Keep out of the sight and reach of children. Accidental ingestion of NSAIDs by children can lead to serious adverse effects. Store in a child-resistant container where possible.
• Original Packaging: Keep Ceclofen 100 mg in its original blister pack or bottle until use. Do not transfer tablets to unmarked containers.
• Expiry Date: Do not use Ceclofen 100 mg after the expiry date printed on the pack. Expired medicines should be disposed of safely in accordance with local pharmaceutical waste disposal guidelines — do not flush down the drain or throw in household rubbish.

Note: If you notice any change in the appearance, colour, or smell of Ceclofen 100 mg tablets, do not use them and consult your pharmacist.

Paediatric Use (Children)

There are currently no adequate clinical data on the safety and efficacy of Ceclofen 100 mg in children. As such, Ceclofen 100 mg is not recommended for use in the paediatric population unless specifically prescribed and supervised by a physician experienced in paediatric care. If anti-inflammatory or analgesic therapy is required in children, age-appropriate alternatives (such as ibuprofen suspension or paracetamol) should be considered in consultation with a paediatrician.

Elderly Patients (Geriatric Use)

Elderly patients (65 years and above) represent a high-risk group for NSAID-related adverse effects due to age-related changes in drug metabolism, renal clearance, and gastrointestinal mucosal integrity. The following precautions apply:

• Use the lowest effective dose for the shortest possible duration to achieve adequate symptom control.
• Regularly monitor renal function (serum creatinine, eGFR), liver function, and blood pressure throughout therapy.
• Screen for gastrointestinal risk factors (prior ulcer history, concurrent anticoagulant use) and consider co-prescribing a proton pump inhibitor (PPI) for gastroprotection.
• Be vigilant for signs of fluid retention, oedema, and worsening heart failure, which are more pronounced in this population.

Patients with Renal Impairment

Ceclofen 100 mg and its metabolites are primarily excreted through the kidneys. In patients with mild-to-moderate renal impairment, Ceclofen 100 mg should be used with caution and at the lowest effective dose, with periodic monitoring of renal function. It is contraindicated in severe renal impairment (creatinine clearance <30 mL/min) due to the risk of drug accumulation and nephrotoxicity.

Patients with Hepatic Impairment

Ceclofen 100 mg is extensively metabolized in the liver. In patients with mild-to-moderate hepatic impairment, a dose reduction may be appropriate, and liver enzymes should be monitored regularly. Ceclofen 100 mg is contraindicated in severe hepatic impairment due to the risk of significantly impaired drug clearance and hepatotoxicity.

Patients with Cardiovascular Disease

Patients with established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, hypertension, or congestive heart failure should use Ceclofen 100 mg only after careful benefit-risk assessment. NSAIDs are associated with a dose- and duration-dependent increased risk of serious arterial thrombotic events, including myocardial infarction and stroke. The risk is greatest with long-term use at high doses.

Patients with Coagulation Disorders

Patients with hereditary bleeding disorders (e.g., haemophilia) or those receiving anticoagulant therapy should use Ceclofen 100 mg only under strict medical supervision with appropriate monitoring of coagulation parameters, as Ceclofen 100 mg may impair platelet function and prolong bleeding time.